Molixan 30 mg/ml 2 ml ampoules 5 pcs

Name: Molixan 30 mg/ml 2 ml ampoules 5 pcs
SKU: 904052024
Availability: InStock

€62.84

SKU: 904052024 Categories: Immune system, Immunostimulants, Medicine, Oncology

Description

– acute severe alcohol intoxication (as part of complex therapy);
– acute and chronic viral hepatitis B, C;

Composition

1 ml of solution contains the active substance: inosine glycyl-cysteinyl-glutamate disodium 10 mg or 30 mg and excipients: sodium acetate trihydrate – 13.6 mg, diluted acetic acid – to pH 6.0, water for injection – up to 1 ml.

Instructions

Intravenously and intramuscularly.

As a solvent for intravenous administration, 0.9% sodium chloride solution or 5% dextrose solution is used.

Recommended treatment regimens:

In the treatment of acute alcohol intoxication – alcoholic coma, against the background of standard detoxification therapy: the drug Molixan® at a dose of 3.0 mg/kg is administered intravenously once (in a stream) with a 0.9% sodium chloride solution, or with a 5% dextrose solution in a ratio of volume 1:1.

For acute viral hepatitis B, the drug Molixan® is administered intravenously or intramuscularly once 10 mg/day every other day throughout the course of symptomatic and detoxification therapy.

In severe forms of acute viral hepatitis B, Molixan® is administered intravenously or intramuscularly once 20 mg/day daily throughout the course of symptomatic and detoxification therapy.

In complex antiviral therapy for chronic viral hepatitis B, the drug Molixan® is administered intravenously or intramuscularly once 30 mg/day three times a week, every other day, throughout the entire course of specific antiviral therapy.

In monotherapy for chronic viral hepatitis B, resistant to specific antiviral therapy or when it is impossible to carry out for medical reasons: the drug Molixan® is administered intravenously or intramuscularly once 30 mg/day three times a week, every other day, for a course of treatment of 24 weeks.

In complex antiviral therapy of chronic viral hepatitis C: the drug Molixan® is administered intravenously or intramuscularly once 60 mg/day three times a week, every other day throughout the entire course of specific antiviral therapy.

In monotherapy for chronic viral hepatitis C, resistant to specific antiviral therapy or when it is impossible to carry out it for medical reasons: the drug Molixan® is administered intravenously or intramuscularly once 60 mg per day, three times a week, every other day, a course of treatment of 24 weeks.

Contraindications

– pregnancy and breastfeeding;

– in children due to lack of experience in medical use;

– individual intolerance to the components of the drug.

Use during pregnancy and breastfeeding

The use of Molixan® during pregnancy and breastfeeding is contraindicated due to the lack of clinical data on safety in these groups of patients.

Special instructions

Treatment with the drug should be carried out under regular medical supervision.

Impact on the ability to drive vehicles and machinery

The drug does not have a negative effect on the ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Side effects

Local allergic reactions are possible: local hyperemia, burning, swelling (at the injection site). Some patients may experience a slight increase in body temperature to 37.1°-37.5° C, pain at the injection site of the drug (in this case, the drug is administered along with 1-2 ml of 0.25% procaine solution).

Pharmacodynamics

Molixan® is an organic salt containing inosine (purine component) and glycyl-cysteinyl-glutamate (peptide component) in a 1:1 ratio. Molixan® regulates the thiol-disulfide metabolism of hepatocytes, induces the expression of enzymes of the first and second phases of xenobiotic detoxification, suppresses the replication of DNA and RNA of viruses that cause hepatitis B and C, stimulates the production of interferons  and  by liver macrophages, interleukin-2 by T-lymphocytes. The cytoprotective and immunomodulatory activities of the drug Molixan® lead to inhibition of hepatocyte cytolysis and resolution of the inflammatory process during toxic and viral lesions of liver cells. The peptide and purine components of Molixan® indirectly affect the metabolism, processes of proliferation, differentiation and apoptosis of liver cells, helping to restore the normal structure of liver tissue. The drug has immunomodulatory, antiviral, hepatoprotective, cardioprotective and neuroprotective effects.

In clinical use – the treatment of acute alcohol intoxication (alcoholic coma), against the background of standard detoxification therapy, Molixan® reduces the time for patients to recover from a coma, normalizes the bioelectrical activity of the brain and the conduction system of the heart, helps normalize the blood gas composition and acid-base balance, level lactate, potassium content, transaminase activity, alkaline

phosphatase, gamma-glutamyl transpeptidase, the level of bilirubin and its fractions, stops the development of changes characteristic of withdrawal syndrome, eliminates anxiety, vegetative-vascular disorders.

During acute and chronic ethanol intoxication in experimental animals, the hepatoprotective effect of the drug Molixan® was manifested in a decrease in the concentration of total bilirubin and a decrease in the activity of blood transaminases (ALT/AST). According to preclinical studies, intravenous administration of the drug at a dose of 30 mg/kg increased the resistance of the rat myocardium to myocardial ischemia-reperfusion injury, reducing the size of the necrosis zone, and had a mild hypotensive effect. In experimental animals introduced into a state of alcohol withdrawal, the drug contributed to a decrease in the level of markers of neuroglial cell damage: neuron-specific enolase and S-100B protein, and a more rapid normalization of neurological symptoms.

Pharmacokinetics

The pharmacokinetics of the drug Molixan® with intravenous administration of a dose of 1 mg/kg is described by a two-part model with the following indicators for the peptide component of the organic salt of the drug Molixan®: the maximum concentration of the peptide component in the blood plasma is 170-180 μg/ml; elimination constant of the peptide component is 0.085 min -1; bioavailability of the peptide component is 90%; total clearance of the peptide component is 20 ml/kg/min; the average retention time of the peptide component is 6-8 minutes; The half-life of the peptide component is 15-20 minutes. The components of the organic salt of the drug Molixan®, peptide and purine components, are metabolized in the organs and tissues of the body to amino acids and purine base derivatives and excreted through the kidneys.medi

Additional information